We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baudax Bio acquired TeraImmune, a privately held company that’s focused on the discovery and development of Treg-based cell therapies for autoimmune diseases. Shares of Baudax Bio soared almost 125% on Jun 30, following the news.
The acquisition will add TeraImmune's TI-168 asset to Baudax Bio's portfolio. TI-168 is a next-generation, autologous FVIII TCR-Treg cell therapy candidate designed to eliminate clotting factor VIII (FVIII) inhibitors in patients with hemophilia A.
An investigational new drug application for TI-168 has been recently approved by the FDA. Baudax Bio believes that with a modest initial budget, it can initiate the phase I/IIa clinical study of TI-168 for the treatment of hemophilia A.
Hemophilia A is a rare genetic bleeding disorder caused by a lack of FVIII.
Shares of Baudax Bio have plunged 63.2% year to date compared with the industry’s 2.7% decline.
Image Source: Zacks Investment Research
The company will continue to advance its existing neuromuscular blockade (NMB) portfolio. It has two clinical-stage NMB candidates — BX1000 and BX2000. BX1000 has recently completed the phase II study, while BX2000 is currently undergoing a dose escalation phase I clinical study.
Additionally, BXRX has developed a proprietary chemical reversal agent that is specifically designed for these NMBs. The candidate is currently undergoing nonclinical and manufacturing studies. The company aims is to file an investigational new drug application for the candidate in the summer of 2023.
The acquisition of TeraImmune was structured as a stock-for-stock transaction. Under the agreement, all outstanding equity interests of TeraImmune were exchanged for a combination of Baudax Bio common stock and newly designated convertible series X non-voting convertible preferred stock.
Subject to shareholders’ approval, each share of the abovementioned preferred stock will automatically convert into 1,000 shares of common stock. Based on these transactions, Baudax Bio equity holders will own approximately 18% of the combined company (following the acquisition) on a pro forma basis.
The potential merger is expected to benefit the shareholders of both companies.
The Zacks Consensus Estimate for Novartis’ 2023 earnings has gone up from $6.56 per share to $6.74 in the past 90 days. Shares of Novartis have risen 11.2% year to date.
NVS’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 5.15%.
The consensus estimate for Akero Therapeutics has narrowed from a loss of $2.96 per share to a loss of $2.80 for 2023 in the past 90 days. Shares of Akero Therapeutics have nosedived 14.8% year to date.
AKRO’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.13%.
The consensus mark for Omega Therapeutics has narrowed from a loss of $2.49 per share to a loss of $2.05 for 2023 in the past 90 days. Shares of the company have rallied 0.2% year to date.
OMGA’s earnings beat estimates in two of the trailing four quarters, met the mark in one and missed in another, delivering an average surprise of 8.24%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Baudax Bio (BXRX) Up 125% on Acquiring TeraImmune
Baudax Bio acquired TeraImmune, a privately held company that’s focused on the discovery and development of Treg-based cell therapies for autoimmune diseases. Shares of Baudax Bio soared almost 125% on Jun 30, following the news.
The acquisition will add TeraImmune's TI-168 asset to Baudax Bio's portfolio. TI-168 is a next-generation, autologous FVIII TCR-Treg cell therapy candidate designed to eliminate clotting factor VIII (FVIII) inhibitors in patients with hemophilia A.
An investigational new drug application for TI-168 has been recently approved by the FDA. Baudax Bio believes that with a modest initial budget, it can initiate the phase I/IIa clinical study of TI-168 for the treatment of hemophilia A.
Hemophilia A is a rare genetic bleeding disorder caused by a lack of FVIII.
Shares of Baudax Bio have plunged 63.2% year to date compared with the industry’s 2.7% decline.
Image Source: Zacks Investment Research
The company will continue to advance its existing neuromuscular blockade (NMB) portfolio. It has two clinical-stage NMB candidates — BX1000 and BX2000. BX1000 has recently completed the phase II study, while BX2000 is currently undergoing a dose escalation phase I clinical study.
Additionally, BXRX has developed a proprietary chemical reversal agent that is specifically designed for these NMBs. The candidate is currently undergoing nonclinical and manufacturing studies. The company aims is to file an investigational new drug application for the candidate in the summer of 2023.
The acquisition of TeraImmune was structured as a stock-for-stock transaction. Under the agreement, all outstanding equity interests of TeraImmune were exchanged for a combination of Baudax Bio common stock and newly designated convertible series X non-voting convertible preferred stock.
Subject to shareholders’ approval, each share of the abovementioned preferred stock will automatically convert into 1,000 shares of common stock. Based on these transactions, Baudax Bio equity holders will own approximately 18% of the combined company (following the acquisition) on a pro forma basis.
The potential merger is expected to benefit the shareholders of both companies.
Baudax Bio, Inc. Price and Consensus
Baudax Bio, Inc. price-consensus-chart | Baudax Bio, Inc. Quote
Zacks Rank & Stocks to Consider
Baudax Bio currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the overall healthcare sector are Novartis (NVS - Free Report) , Akero Therapeutics (AKRO - Free Report) and Omega Therapeutics , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Novartis’ 2023 earnings has gone up from $6.56 per share to $6.74 in the past 90 days. Shares of Novartis have risen 11.2% year to date.
NVS’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 5.15%.
The consensus estimate for Akero Therapeutics has narrowed from a loss of $2.96 per share to a loss of $2.80 for 2023 in the past 90 days. Shares of Akero Therapeutics have nosedived 14.8% year to date.
AKRO’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.13%.
The consensus mark for Omega Therapeutics has narrowed from a loss of $2.49 per share to a loss of $2.05 for 2023 in the past 90 days. Shares of the company have rallied 0.2% year to date.
OMGA’s earnings beat estimates in two of the trailing four quarters, met the mark in one and missed in another, delivering an average surprise of 8.24%.